Citations

Showing 10 of 108152 citations.

Quantity and quality of mental activities and the risk of incident mild cognitive impairment
Syrjanen, Jeremy A. , Vassilaki, Maria , Kremers, Walter K. , Petersen, Ronald C. , Geda, Yonas E. , Krell-Roesch, Janina, Geda, Yonas E , Kremers, Walter K , Krell‐Roesch, Janina , Machulda, Mary M. , Mielke, Michelle M. , Knopman, David S.

Mayo Clinic

Neurology | July 11, 2019 | Volume: 93 | Issue: 6 | Pages: No page available

10.1212/wnl.0000000000007897 | PMID 31292224 Get It

Trial of Galcanezumab in Prevention of Episodic Cluster Headache
Goadsby, Peter J. , Leone, Massimo , Bardos, Jennifer, Oakes, Tina M. , Millen, Brian A. , Zhou, Chunmei, Dowsett, Sherie A. , Aurora, Sheena K. , Ahn, Andrew H. , Yang, Jyun-Yan, Conley, Robert R., Martinez, James M. , Bardos, Jennifer N, Goadsby, Peter J , Dodick, David W.

Mayo Clinic

New England Journal of Medicine | July 10, 2019 | Volume: 381 | Issue: 2 | Pages: 132-141

10.1056/nejmoa1813440 | PMID 31291515 Get It

Reply to Kollef et al
Schreier, Diana J., Frazee, Erin N. , Rule, Andrew D.

Mayo Clinic

Clinical Infectious Diseases | July 10, 2019 | Volume: 70 | Issue: 7 | Pages: 1521-1521

10.1093/cid/ciz644 | PMID 31297521 Get It

Characterization of Cellular Sources and Circulating Levels of Extracellular Vesicles in a Dietary Murine Model of Nonalcoholic Steatohepatitis
Liu, Huimin , Mauer, Amy S. , Raiter, Abagail M., Bandla, Harikrishna, Mounajjed, Taofic, Yin, Ziying , Glaser, Kevin J. , Yin, Meng , Li, Jiahui , Raiter, Abagail, Malhi, Harmeet , Yin, Meng , Yin, Ziying , Li, Jiahui , Lucien, Fabrice , Li, Jiahui

Mayo Clinic

Hepatology Communications | July 10, 2019 | Volume: 3 | Issue: 9 | Pages: 1235-1249

10.1002/hep4.1404 | PMID 31497744 Get It

Circulating extracellular vesicles (EVs) are a novel and emerging biomarker for nonalcoholic steatohepatitis (NASH). It has been demonstrated that total circulating EVs and hepatocyte‐derived EVs are elevated in male mice with diet‐induced NASH. How hepatocyte‐derived EVs change over time and other cellular sources of EVs in NASH have not been determined. Our objective was to define the quantitative evolution of hepatocyte‐derived, macrophage‐derived, neutrophil‐derived, and platelet‐derived EVs in male and female mice with dietary NASH. Fluorescently labeled antibodies and a nanoscale flow cytometer were used to detect plasma levels of EVs. Asialoglycoprotein receptor 1 (ASGR1) and cytochrome P450 family 2 subfamily E member 1 (CYP2E1) are markers of hepatocyte‐derived EVs; galectin 3 is a marker of macrophage‐derived EVs; common epitope on lymphocyte antigen 6 complex, locus G/C1 (Ly‐6G and Ly‐6C) is a marker of neutrophil‐derived EVs; and clusters of differentiation 61 (CD61) is a marker of platelet‐derived EVs. Nonalcoholic fatty liver disease activity score (NAS) was calculated using hematoxylin and eosin‐stained liver sections, and magnetic resonance imaging (MRI) was used for measurement of the fat fraction and elastography. Hepatocyte‐derived EVs increased in both male and female mice at 12 and 10 weeks of feeding, respectively, and remained elevated at 24 weeks in both male and female mice and at 48 weeks in male mice and 36 weeks in female mice. Macrophage‐ and neutrophil‐derived EVs were significantly elevated at 24 weeks of dietary feeding concomitant with the histologic presence of inflammatory foci in the liver. In fat‐, fructose‐, and cholesterol‐ (FFC) fed male mice, platelet‐derived EVs were elevated at 12, 24, and 48 weeks, whereas in female mice, platelet derived EVs were significantly elevated at 24 weeks. Hepatocyte‐, macrophage‐ and neutrophil‐derived EVs correlated well with the histologic NAS. Conclusion: Circulating cell‐type‐specific EVs may be a novel biomarker for NASH diagnosis and longitudinal follow up.
Diagnostic Accuracy of Endobronchial Ultrasound Transbronchial Needle Aspiration in Lymphoma. A Systematic Review and Meta-Analysis
Labarca, Gonzalo , Sierra‐Ruiz, Melibea , Kheir, Fayez , Majid, Adnan , Mehta, Hiren J. , Jantz, Michael A., Fernández-Bussy, Sebastián , Mehta, Hiren J , Labarca, Gonzalo , Folch, Erik E.

Mayo Clinic

Annals of the American Thoracic Society | July 10, 2019 | Volume: 16 | Issue: 11 | Pages: 1432-1439

10.1513/annalsats.201902-175oc | PMID 31291126 Get It

Abstract Rationale Endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive method used to diagnose suspected mediastinal lymph nodes or masses. However, the accuracy of the diagnosis in patients with suspected lymphoma is unclear. Objectives To evaluate the diagnostic yield of EBUS-TBNA in patients with suspected lymphoma. Methods A literature search including EMBASE, MEDLINE, Cochrane Library, and Google Scholar was performed by two reviewers. Included articles were evaluated using the QUADAS-2 tool and meta-analysis with a binary method model to compare the sensitivity, specificity, and summary receiver operating characteristic curve in patients with suspected lymphoma. Results Fourteen studies (425 participants) were pooled in the analysis. EBUS-TBNA reported an overall sensitivity of 66.2% (confidence interval [CI], 55–75.8%; I 2 = 76.2%) and specificity of 99.3% (CI, 98.2–99.7%; I 2 = 40%). For a new diagnosis of lymphoma, 13 studies including 243 participants reported sensitivity of 67.1% (CI, 54.2–77.9%; I 2 = 66.8%) and specificity of 99.6% (CI, 99.1–99.8%; I 2 = 0%). For recurrence of lymphoma, 11 studies including 166 participants reported sensitivity of 77.8% (CI, 68.1–85.2%; I 2 = 20.2%) and specificity of 99.5% (CI, 98.9–99.8%; I 2 = 0%). In the recurrence group, we found the use of rapid onsite examination, sample size, and flow cytometry increased the sensitivity of EBUS-TBNA, albeit a potential source of heterogeneity. Conclusions EBUS-TBNA has fair sensitivity for identifying a new diagnosis of lymphoma and fair to good sensitivity for identifying recurrence. Trial Registry PROSPERO CRD42018102773 https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=102773.
Genome-wide association study of cerebral small vessel disease reveals established and novel loci
Chung, Jaeyoon , Marini, Sandro , Pera, Joanna, Norrving, Bo, Jiménez-Conde, Jordi , Roquer, Jaume, Tirschwell, David L, Brown, Devin L. , Silliman, Scott, Worrall, Bradford B. , Demel, Stacie L , Greenberg, Steven M. , Słowik, Agnieszka , Lindgren, Arne, Schmidt, Reinhold , Sargurupremraj, Muralidharan , Tiedt, Steffen, Malik, Rainer, Debette, Stéphanie , Dichgans, Martin , Langefeld, Carl D. , Woo, Daniel , Anderson, Christopher D. , Tirschwell, David , Marini, Sandro , Dichgans, Martin , Debette, Stephanie , Fernández‐Cadenas, Israel , Selim, Magdy H. , Meschia, James F. , Lindgren, Arne, Traylor, Matthew , Tiedt, Steffen , Rosand, Jonathan M.

Mayo Clinic

Brain | July 10, 2019 | Volume: 142 | Issue: 10 | Pages: 3176-3189

10.1093/brain/awz233 | PMID 31430377 Get It

Intracerebral haemorrhage (ICH) and small vessel ischaemic stroke (SVS) are the most severe manifestations of cerebral small vessel disease. In a cross-phenotype genome-wide association analysis, Chung et al. identify two novel associations at 2q33 and 13q34 plus a previously identified locus at 1q22 for non-lobar ICH and SVS risk.
Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease
Steinhart, A. Hillary , Bressler, Brian , Khanna, Reena , Afif, Waqqas , Bitton, Alain , Borgaonkar, Mark , Chauhan, Usha, Halloran, Brendan P. , Jones, Jennifer , Kennedy, Erin , Meddings, Jonathan B., Plamondon, Sophie , Rosenfeld, Greg , Seow, Cynthia H. , Williams, Chadwick, Bernstein, Çharles N. , Panaccione, Remo , Marshall, John K. , Targownik, Laura E. , Leontiadis, Grigorios I. , Loftus, Edward V. , Moayyedi, Paul , Murthy, Sanjay K. , Schwartz, David A. , Bernstein, Charles Noah

Mayo Clinic

Journal of the Canadian Association of Gastroenterology | July 10, 2019 | Volume: 2 | Issue: 3 | Pages: e1-e34

10.1093/jcag/gwz019 | PMID 31294378 Get It

Abstract Background & Aims Crohn’s disease (CD) is a lifelong illness with substantial morbidity, although new therapies and treatment paradigms have been developed. We provide guidance for treatment of ambulatory patients with mild to severe active luminal CD. Methods We performed a systematic review to identify published studies of the management of CD. The quality of evidence and strength of recommendations were rated according to the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Statements were developed through an iterative online platform and then finalized and voted on by a group of specialists. Results The consensus includes 41 statements focused on 6 main drug classes: antibiotics, 5-aminosalicylate, corticosteroids, immunosuppressants, biologic therapies, and other therapies. The group suggested against the use of antibiotics or 5-aminosalicylate as induction or maintenance therapies. Corticosteroid therapies (including budesonide) can be used as induction, but not maintenance therapies. Among immunosuppressants, thiopurines should not be used for induction, but can be used for maintenance therapy for selected low-risk patients. Parenteral methotrexate was proposed for induction and maintenance therapy in patients with corticosteroid-dependent CD. Biologic agents, including tumor necrosis factor antagonists, vedolizumab, and ustekinumab, were recommended for patients failed by conventional induction therapies and as maintenance therapy. The consensus group was unable to clearly define the role of concomitant immunosuppressant therapies in initiation of treatment with a biologic agent. Conclusions Optimal management of CD requires careful patient assessment, acknowledgement of patient preferences, evidence-based use of existing therapies, and thorough assessment to define treatment success.
DNA–SWCNT Biosensors Allow Real-Time Monitoring of Therapeutic Responses in Pancreatic Ductal Adenocarcinoma
Gong, Xun , Wang, Enfeng , Dutta, Shamit K., Caplette, Joseph R., Son, Manki, Nguyen, Freddy T. , Strano, Michael S. , Gong, Xun , Nguyen, Freddy T , Bhattacharya, Santanu , Mukhopadhyay, Debabrata

Mayo Clinic

Cancer Research | July 10, 2019 | Volume: 79 | Issue: 17 | Pages: 4515-4523

10.1158/0008-5472.can-18-3337 | PMID 31292162 Get It

Abstract Pancreatic ductal adenocarcinoma (PDAC) is a highly desmoplastic cancer with limited treatment options. There is an urgent need for tools that monitor therapeutic responses in real time. Drugs such as gemcitabine and irinotecan elicit their therapeutic effect in cancer cells by producing hydrogen peroxide (H2O2). In this study, specific DNA-wrapped single-walled carbon nanotubes (SWCNT), which precisely monitor H2O2, were used to determine the therapeutic response of PDAC cells in vitro and tumors in vivo. Drug therapeutic efficacy was evaluated in vitro by monitoring H2O2 differences in situ using reversible alteration of Raman G-bands from the nanotubes. Implantation of the DNA–SWCNT probe inside the PDAC tumor resulted in approximately 50% reduction of Raman G-band intensity when treated with gemcitabine versus the pretreated tumor; the Raman G-band intensity reversed to its pretreatment level upon treatment withdrawal. In summary, using highly specific and sensitive DNA-SWCNT nanosensors, which can determine dynamic alteration of hydrogen peroxide in tumor, can evaluate the effectiveness of chemotherapeutics. Significance: A novel biosensor is used to detect intratumoral hydrogen peroxide, allowing real-time monitoring of responses to chemotherapeutic drugs.
Modulating the TSH Receptor with High Specificity Gets a Step Closer Toward Use in Clinical Practice
Banga, J. Paul, Stan, Marius N.

Mayo Clinic

Clinical Thyroidology | July 10, 2019 | Volume: 31 | Issue: 7 | Pages: 295-298

10.1089/ct.2019;31.295-298 Get It

Neuromodulation for the Acute and Preventive Therapy of Migraine and Cluster Headache
Robbins, Matthew S. , Halker Singh, Rashmi B, Robbins, Matthew S , Singh, Rashmi B. Halker , Ailani, Jessica

Mayo Clinic

Headache: The Journal of Head and Face Pain | July 10, 2019 | Volume: 59 | Issue: S2 | Pages: 33-49

10.1111/head.13586 | PMID 31291017 Get It

Headache disorders are among the most common and disabling medical conditions worldwide. Pharmacologic acute and preventive treatments are often insufficient and poorly tolerated, and the majority of patients are unable to adhere to their migraine treatments due to these issues. With improvements in our understanding of migraine and cluster headache pathophysiology, neuromodulation devices have been developed as safe and effective acute and preventive treatment options. In this review, we focus on neuromodulation devices that have been studied for migraine and cluster headache, with special attention to those that have gained food and drug administration (FDA) clearance. We will also explore how these devices can be used in patients who might have limited pharmacologic options, including the elderly, children, and pregnant women.